FDA 483 OBSERVATION · #68 OF 1,945 MOST-CITED
DMR - not or inadequately maintained
FDA cited this observation 371 times across 339 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
21 CFR 820.181 (Device master record) is a Quality System Regulation section; since QMSR took effect on 2 February 2026 FDA inspects this as “Medical Device File”: ISO 13485 clause 4.2.3 (CP 7382.850 Attachment A).
The Device Master Record (DMR) — the compilation of records defining how a device is produced — was not maintained or was inadequate, so the specifications and procedures for manufacturing the device were incomplete or missing.
Why FDA writes it — The DMR is the recipe for a device: specifications, production processes, quality-assurance procedures, packaging, and labeling. An incomplete DMR means the device is made without a controlled definition of how it should be made, so consistency and conformance cannot be assured.
- Maintain a DMR for each type of device, including device specifications, production process specifications, quality-assurance procedures and acceptance criteria, packaging and labeling specifications, and installation/servicing procedures where applicable.
- Keep the DMR current through change control.
- Ensure each DMR is prepared and approved per 21 CFR 820.40 (document controls).
- Reference the DMR from the device history record so production traces back to it.
- DMR content scattered and never compiled/controlled as a defined record.
- DMR not updated when the device or process changes, so it no longer defines production.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.6× the rate of the average FDA-cited firm (12.7% vs 7.8%), across 339 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
A device master record has not been adequately maintained.
A device master record has not been maintained.
A device master record has not been maintained.
A device master record has not been adequately maintained.
A device master record has not been adequately maintained.
A device master record has not been maintained.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →